Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-week study of glycopyrrolate + formoterol for post-tuberculosis COPD
ChiCTR2500103088Phase 4Not yet recruiting
- Sponsor
- Guangzhou Chest Hospital
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of glycopyrronium, formoterol and salbutamol in chronic obstructive pulmonary disease (COPD), sponsored by Guangzhou Chest Hospital. Primary endpoint: Change from baseline in pre-bronchodilator FEV1 at 12 weeks. Planned start May 2025; status: not yet recruiting.
02
Drugs
glycopyrroniumformoterolsalbutamol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ChiCTR2500103088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103088.